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Abstract 
The calcium ion (Ca2 +) is an important signaling molecule implicated in many cellular 
processes, and the remodeling of Ca2 +homeostasis is a feature of a variety of pathologies. 
Typical methods to assess Ca2 + signaling in cells often employ small molecule fluorescent dyes, 
which are sometimes poorly suited to certain applications such as assessment of cellular 
processes, which occur over long periods (hours or days) or in vivo experiments. Genetically 
encoded calcium indicators are a set of tools available for the measurement of Ca2 + changes 
in the cytosol and subcellular compartments, which circumvent some of the inherent 
limitations of small molecule Ca2 + probes. Recent advances in genetically encoded calcium 
sensors have greatly increased their ability to provide reliable monitoring of Ca2 + changes in 
mammalian cells. New genetically encoded calcium indicators have diverse options in terms 
of targeting, Ca2 + affinity and fluorescence spectra, and this will further enhance their 
potential use in high-throughput drug discovery and other assays. This review will outline the 
methods available for Ca2 + measurement in cells, with a focus on genetically encoded calcium 
sensors. How these sensors will improve our understanding of the deregulation of 
Ca2 + handling in disease and their application to high-throughput identification of drug leads 
will also be discussed. 
 
Abbreviations 
[Ca2+]CYT resting cytosolic free calcium ion concentration 
AM acetoxymethyl 
ATP adenosine triphosphate 
BAPTA 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid 
Ca2+ calcium ion 
ER endoplasmic reticulum 
FLIPR fluorescence imaging plate reader 
FRET Förster resonance energy transfer 
GECI genetically encoded calcium indicator 
GFP green fluorescent protein 
IP3 inositol 1,4,5-trisphosphate 
IP3R 1,4,5-trisphosphate-activated receptor 
NFAT nuclear factor of activated T cells 
PS1 presenilin-1 
RyR ryanodine receptor 
SR/ER sarcoplasmic/endoplasmic reticulum 
TRP transient receptor potential 
 
1 Introduction 
The calcium ion (Ca2 +) is an important intracellular second messenger, the movement 
of which is responsible for the regulation of a variety of cellular processes. These include 
proliferation, excitation/contraction coupling, cell death, gene transcription, and cell motility 
(Berridge, Bootman, & Roderick, 2003; Clapham, 2007). Simultaneous regulation of these and 
other Ca2 +-dependent processes is achieved via a suite of Ca2 + channels, pumps, exchangers, 
and regulators. Together, they function to manipulate the temporal and spatial aspects of the 
Ca2 + signal (Berridge, 2000; Berridge et al., 2003; Prevarskaya, Ouadid-Ahidouch, Skryma, & 
Shuba, 2014). Plasma membrane Ca2 + pumps are responsible for preserving a large 
plasmalemmal concentration gradient for Ca2 +, which consists of a resting cytosolic free 
Ca2 +concentration ([Ca2 +]CYT) of approximately ~ 100 nM. This is in stark contrast to the high 
concentration of free Ca2 + in the extracellular space (~ 1–2 mM) (Berridge, 2000; Clapham, 
2007). Fig. 1 outlines the key classes of Ca2 +channels located in mammalian cells, with the 
approximate free Ca2 + levels for the cytosol, sarcoplasmic/endoplasmic reticulum (SR/ER), 
and mitochondria. 
Alterations in Ca2 + signaling have been linked to the pathophysiology of several 
diseases including cardiovascular disease, neurological disorders, and cancer (Brini, Cali, 
Ottolini, & Carafoli, 2014; Fearnley, Roderick, & Bootman, 2011; Monteith, McAndrew, Faddy, 
& Roberts-Thomson, 2007). Targeting regulators of Ca2 + signaling therefore may represent an 
area of opportunity for the identification of new therapies for such diseases. Modulating 
Ca2 + signaling has already been demonstrated to have clinical relevance. Examples include the 
L-type voltage-gated Ca2 + channel blockers such as amlodipine and nifedipine, which have 
been widely used for hypertension (Elliott & Ram, 2011; Godfraind, 2014). Other examples 
include the N-type Ca2 + channel blocker ziconitide which can be used in the treatment of 
severe chronic pain (Schmidtko, Lotsch, Freynhagen, & Geisslinger, 2010) and the clinical trial 
of an inhibitor of the Ca2 + ion permeable transient receptor potential V4 (TRPV4) channel 
(GSK2798745) in congestive heart failure patients (GlaxoSmithKline, 2000). 
Studies investigating alterations in Ca2 + signaling in disease often focus on changes in 
expression of Ca2 + channels, pumps, or their regulators. Some examples include the 
identification of increased expression of inositol 1,4,5-trisphosphate (IP3)-activated receptors 
(IP3Rs) in cardiomyocytes isolated from spontaneously hypertensives rats, a model of cardiac 
hypertrophy (Harzheim et al., 2009), and the down regulation of plasma membrane 
Ca2 + ATPase four levels in colon cancers (Aung et al., 2009). While studies reporting altered 
expression of calcium channels and pumps have improved our understanding of many 
diseases, another important consideration is changes to the Ca2 + signal itself. The significance 
of assessment of Ca2 + levels is evident when one considers Ca2 + permeable ion channels. 
Overexpression of a plasmalemmal ion channel per se is unlikely to alter calcium signaling in 
disease if the channel is not active due to the absence of appropriate stimuli or a lack of 
appropriate trafficking to the plasma membrane. 
Changes in Ca2 + signaling in disease is almost always likely to be the result of a 
symphony of changes, not only due to changes in expression but also due to alterations in 
protein localization or changes in posttranslational modifications (Stewart, Yapa, & Monteith, 
2015). One way to measure the sum of these changes and their impact on disease, is via the 
measurement of the Ca2 + signal directly. Advances in our knowledge of such changes have 
been catalyzed by improvements in the methods to measure intracellular Ca2 +. These 
improvements have been the development of tools (e.g., small molecule Ca2 +-sensitive 
fluorescent dyes and genetically encoded calcium indicators (GECIs)) and their use with 
advanced imaging methodologies. As will be outlined in this review, the recent expansion of 
GECIs continues to diversify the tools available to measure Ca2 + changes in disease. With the 
range of sensors now available, it is often now just a matter of the thoughtful selection of the 
correct probe for the specific application. This review will focus on GECIs and how these tools 
can be applied to the study of Ca2 + signaling in disease and in high-throughput screening for 
drug discovery. 
 
2 The Calcium Signal in Disease 
Remodeling of intracellular Ca2 + signaling is a key component of several diseases 
(Brini, Ottolini, Cali, & Carafoli, 2013; Missiaen et al., 2000; Roderick & Cook, 2008). Research 
into pathological changes of Ca2 + signaling in neurodegenerative disease, cardiovascular 
disease, and cancer predominate. In Alzheimer's disease, resting cytosolic free Ca2 + has been 
reported to be elevated (Kuchibhotla, Lattarulo, Hyman, & Bacskai, 2009) and this remodeling 
of intracellular Ca2 + signaling is thought to be the result of several mechanisms (Berridge, 
2014). In presenilin (PS1) mutation models of familial Alzheimer's disease, upregulation of 
ryanodine receptor (RyR) Ca2 + channels (Chan, Mayne, Holden, Geiger, & Mattson, 2000) and 
increased activity of IP3Rs may enhance Ca2 + store release from the SR/ER (Cheung et al., 
2008). Given the role of Ca2 + signaling in apoptosis and necrosis, this dysregulation of 
Ca2 +present in Alzheimer's disease and other neurodegenerative disorders is speculated to 
contribute to characteristic neuronal cell death associated with a variety of pathologies 
(Mattson & Chan, 2003). Changes in the handling of Ca2 +have also been identified in cardiac 
hypertrophy and heart failure. For example, the Cav3.2 voltage-gated calcium channel has 
been implicated in cardiac hypertrophy, in mice, Cav3.2 knockout was found to be protective 
against induction of cardiac hypertrophy, a process thought to be the consequence of 
reduced calcineurin/nuclear factor of activated T cells (NFAT) activation (Chiang et al., 2009). 
The 1,4,5-triphosphate receptor, type 3 (IP3R3) Ca2 + channel, while normally having minimal 
expression in cardiac tissue, is found to be upregulated in patients with heart failure (Go et 
al., 1995) and it has been proposed that the result of this upregulation is the sensitization of 
RyRs to increase Ca2 + store release (Harzheim et al., 2009). 
As discussed earlier, calcium signaling is integral to normal cell physiology and has an 
important role in a variety of processes ranging from proliferation and hormone secretion to 
cell death (Berridge et al., 2003). In cancer, many of these cell functions are altered which can 
contribute to disease progression (Hanahan & Weinberg, 2011). It is therefore unsurprising 
that the dysregulation of Ca2 + signaling is a reported feature of some cancers. Alteration of 
Ca2 + signaling has been identified in cancers of the prostate, breast, colon, and ovaries 
(Monteith, Davis, & Roberts-Thomson, 2012; Prevarskaya, Zhang, & Barritt, 2007; Roderick & 
Cook, 2008). As an example, the Ca2 + channel TRPV6 can be upregulated in prostate cancer 
(Peng et al., 2001) and this is thought to function as a mechanism to increase [Ca2 +]CYT to 
promote proliferation (Lehen'kyi, Flourakis, Skryma, & Prevarskaya, 2007). Indeed, levels of 
TRPV6 have been suggested as a marker of prostate cancer progression (Fixemer, 
Wissenbach, Flockerzi, & Bonkhoff, 2003). TRPV6 can also be overexpressed in breast cancer 
(Bolanz, Hediger, & Landowski, 2008; Dhennin-Duthille et al., 2011) and has been associated 
with the aggressive estrogen receptor-negative subtype (Peters et al., 2012). Several other 
calcium channels and pumps have been linked to breast cancer, these include other TRP 
channels such as TRPC1 (Dhennin-Duthille et al., 2011) and TRPM7 (Guilbert et al., 2009), 
members of the store-operated Ca2 + entry family ORAI1 (McAndrew et al., 2011) and ORAI3 
(Faouzi et al., 2011), and pumps that are responsible for Ca2 + efflux across the plasma 
membrane such as PMCA2 (Lee, Roberts-Thomson, & Monteith, 2005). 
The diversity of disorders associated with altered Ca2 + signaling has propelled the 
need for tools to improve our understanding of the contribution of these changes to disease 
pathophysiology. With recent advancements, we also now have the capabilities and 
measurement tools to identify compounds able to disrupt or prevent Ca2 + alterations in some 
diseases which are currently not effectively treated. Therefore, monitoring the Ca2 + signal is 
an increasingly important method for drug discovery. 
 
3 The Calcium Signal as a Tool in Biomolecular Screening 
The concept of Ca2 + signaling assessment as an endpoint for biomolecular screening 
in drug discovery is not new; however, recent advances in Ca2 + measurement methods 
including those related to genetically encoded Ca2 + indicators will allow further progress in 
this field. Likewise improvements in high-throughput screening instrumentation are further 
contributing to the development of this area. 
Assays investigating alterations in the Ca2 + signal not only provide a platform to better 
identify the mechanism of Ca2 + changes in disease, but they also allow the screening of 
compounds able to alter intracellular Ca2 + and the nature of the Ca2 + signal. For example, in 
neuroscience, where Ca2 +oscillations can be a surrogate for activity (Smetters, Majewska, & 
Yuste, 1999), assessment of [Ca2 +]CYT may allow the identification of compounds able to alter 
neuronal activity and synaptic transmission (Woods & Padmanabhan, 2012). Another 
example is the screening of compounds potentially able to promote cancer cell death induced 
by chemotherapeutic drugs, through assessment of the high cytosolic or mitochondrial 
Ca2 + levels associated with cell death. Screening for Ca2 + changes could allow the identification 
of lead compounds that are not capable of inducing cell death alone, but able to augment 
free Ca2 + levels to a sufficient extent to promote the effectiveness of existing therapies. 
The above examples of assessment of Ca2 + levels as a biomolecular screen are easily 
applied to plate reader devices, such as the fluorescence imaging plate reader (FLIPRTETRA; 
Molecular Devices, Sunnyvale, CA, USA) for high-throughput assays (Monteith & Bird, 2005). 
An increasing area of interest is the development of cell-based assays involving high content 
screening (Mattiazzi Usaj et al., 2016). Instead of a single measurement from a population of 
cells (such as produced in plate reader assays), high content screening allows dynamic 
visualization of cells at a single-cell level often with simultaneous assessment of other cellular 
functions through other fluorescence probes with distinct fluorescence spectra (Zanella, 
Lorens, & Link, 2010). For example, this has been used in a genome-wide siRNA screen for 
regulators of Parkin, a gene important in mitochondrial damage in Parkinson's disease 
(Hasson et al., 2013). Candidate genes were identified by examining Parkin translocation in 
HeLa cells, determined by loss of nuclear localized green fluorescent protein (GFP)-tagged 
Parkin fluorescence (Hasson et al., 2013). This was identified by measuring Parkin-GFP 
colocalization with spectrally distinct Hoechst 33342 fluorescence, with some hits discarded 
based on mitochondrial depletion identified by a third fluorescence channel (Hasson et al., 
2013). High content screening drastically increases the depth of information uncovered from 
a bioassay and is well suited to investigation of the nature of Ca2 + alterations induced by 
compounds or extracts from screening libraries. Some examples include the identification of 
heterogeneity in the response between individual cells and cell populations; changes in 
subcellular Ca2 + levels (e.g., mitochondria), and how these relate to changes in the 
cytosol; Ca2 + oscillation, and Ca2 + wave rates; and simultaneous assessment of Ca2 + changes 
with other events (e.g., morphology or transcription factor translocation). When developing 
such phenotypic measurements of Ca2 + signaling success requires streamlined analysis, 
including features such as automated cell detection and cell tracking. These requirements are 
common for other high content imaging assays, such as those investigating cellular migration, 
proliferation, or protein colocalization (Boutros, Heigwer, & Laufer, 2015; Mattiazzi Usaj et 
al., 2016). 
The success of cell-based assays when applied to Ca2 + signaling is critically dependent 
on the method for measuring intracellular calcium. The next focus of this review will be to 
highlight some of the methods to measure intracellular calcium levels and how these may 
influence their application to studying disease processes or biomolecular screening. There will 
be an emphasis on GECIs and how recent developments in this field can be leveraged for these 
types of assays. 
 
4 Methods to Measure Cytosolic Calcium 
The intricacies of intracellular Ca2 + signaling are progressively becoming unraveled 
with advances in the methods to measure intracellular free Ca2 +. Development of such 
methods has highlighted the importance of spatial and temporal aspect of the Ca2 + signal for 
differential regulation of Ca2 +-dependent functions (Rudolf, Mongillo, Rizzuto, & Pozzan, 
2003). Ca2 + indicators are often classified into one of two groups: small molecule fluorescent 
Ca2 + dyes or protein-based GECIs. 
 
4.1 Small Molecule Fluorescent Dyes for the Assessment of 
Ca2 + Signaling 
Small molecule fluorescent calcium indicators are organic molecules capable of 
undergoing a change in fluorescence in response to Ca2 + binding. These compounds were 
developed over 30 years ago (Grynkiewicz, Poenie, & Tsien, 1985; Tsien, Pozzan, & Rink, 1982) 
and continue to be widely used for Ca2 + measurement. Their extensive use is related to their 
high performance (high fluorescence intensity, large dynamic range, fast kinetics, linear 
responses) (Lock, Parker, & Smith, 2015; Mank & Griesbeck, 2008), established protocols 
(Takahashi, Camacho, Lechleiter, & Herman, 1999), and the now vast array of variants 
available—including a range of Ca2 + affinities and emission wavelengths. 
Small molecule Ca2 + indicators may be intensiometric (or single wavelength) or 
ratiometric. Intensiometric probes only undergo an increase in fluorescence intensity on 
binding Ca2 +; in contrast, ratiometric probes also exhibit a shift in fluorescence spectra upon 
Ca2 + binding. With appropriate calibration ratiometric, dyes can be used for accurate 
quantitative assessment of absolute free Ca2 + (Bootman, Rietdorf, Collins, Walker, & 
Sanderson, 2013). Small molecule Ca2 + dyes are mostly modeled on the structure of the 
calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA) coupled 
to a fluorescent reporter group (Grynkiewicz et al., 1985). This BAPTA structural element has 
a high affinity for Ca2 +, though this structure can be modified to adjust Ca2 + affinity to allow 
detection at a range of Ca2 +concentrations (Oheim et al., 2014). Probes are most commonly 
used in an acetoxymethyl (AM) ester form, allowing free passage of the otherwise highly 
charged dye across the phospholipid bilayer (Paredes, Etzler, Watts, Zheng, & Lechleiter, 
2008). Once the AM ester form has crossed the plasma membrane, intracellular esterases 
generate the Ca2 + sensitive ionized moiety (Thomas et al., 2000). 
Some applications for Ca2 + measurement are poorly suited to the use of small 
molecule fluorescent dyes. One example is long-term Ca2 + monitoring. Dye leakage is a 
common occurrence (Palmer & Tsien, 2006; Thomas et al., 2000) and can occur within 30 min 
of dye loading dependent on cell types and/or experimental conditions (Paredes et al., 2008). 
This limitation can be particularly evident in some cancer cell lines that express multidrug-
resistance proteins that can transport many of these probes (Homolya et al., 1993). Over time, 
fluorescent dyes also have the tendency to sequester into subcellular Ca2 +stores such as the 
endoplasmic reticulum (ER) (Mank & Griesbeck, 2008) where Ca2 + levels may saturate probes 
appropriate for [Ca2 +]CYT measurements. Together, these limitations can reduce the reliability 
of these indicators for long-term Ca2 + measurements. 
A further weaknesses of small molecule calcium dyes is their inability to be readily 
targeted to specific tissues, cell types, or subcellular locations (Demaurex, 2005). Dyes can 
accumulate in subcellular regions (Oheim et al., 2014), though it is often not without 
background fluorescence in other areas such as the cytosol (Petrou et al., 2000). One example 
are members of the rhodamines that can accumulate in the mitochondria that has allowed 
probes such as Rhod-2 to be used to assess mitochondrial Ca2 + changes in mammalian cells 
(Babcock, Herrington, Goodwin, Park, & Hille, 1997). Fluorescent dyes are also poorly suited 
to in vivo studies (Helmchen & Waters, 2002; Whitaker, 2010). This is related to challenges in 
dye loading in vivo, including the inability to load specific cell types, loss of the probe due to 
efflux mechanisms, and probe sequestration. Although there are some examples where in 
vivo measurements have been achieved (Helmchen, Svoboda, Denk, & Tank, 1999; Stosiek, 
Garaschuk, Holthoff, & Konnerth, 2003), such approaches are unsuited to most in vivo 
applications. 
 
4.2 GECIs for the Assessment of Ca2 + Signaling 
GECIs can overcome some of the issues associated with small molecule fluorescent 
dyes. One of the principle advantages of GECIs is that these sensors enable long-term, repeat 
[Ca2 +] measurement. Instead of experiments over minutes or hours, GECIs can allow repeated 
measurement over an extended period, up to many weeks or months (Aramuni & Griesbeck, 
2013). This has led to these sensors being successfully introduced into several organisms for 
in vivo intracellular Ca2 + studies, from Drosophila (Tian et al., 2009) to mice (Hasan et al., 
2004), to even primates (Santisakultarm et al., 2016). 
Arguably, the development and application of GECIs has predominantly been driven 
by neuroscience research, where the disadvantages of small molecule Ca2 + probes are 
particular evident (Mank & Griesbeck, 2008; Tian, Hires, & Looger, 2012). Unlike small 
molecule fluorescent Ca2 + dyes, GECIs can be readily targeted to specific tissues, cell 
populations, or subcellular location through the addition of an appropriate promoter or 
targeting sequence. For example, GECIs allow Ca2 + measurement of astrocytes among a 
population of neurons (Shigetomi, Kracun, Sofroniew, & Khakh, 2010), or can be targeted to 
presynaptic neurons (Jackson & Burrone, 2016) or even a specific interneuron subtype 
(Hinckley & Pfaff, 2013). This targeting feature also opens up the investigation of Ca2 + handling 
in particular organelles such as the ER or mitochondria, through the introduction of a 
targeting sequence (recently reviewed by Suzuki, Kanemaru, & Iino, 2016). 
The basic structure of most GECIs consists of a Ca2 + sensing element coupled to one 
or two fluorophores, capable of an alteration in fluorescence with Ca2 + binding. Calmodulin is 
a common binding domain for GECIs. An alternative approach uses troponin C as a binding 
domain, a protein suggested to have less potential for endogenous interaction (Heim & 
Griesbeck, 2004). 
As outlined later, genetically encoded calcium sensors use either fluorescent or 
luminescent proteins to report changes in calcium signaling. 
 
4.2.1 Aequorin-Based GECIs 
Aequorin is a bioluminescence-based indicator first isolated from the Aequorea 
victoria jellyfish (Shimomura, Johnson, & Saiga, 1962). In the presence of an external cofactor 
(coelenterazine), aequorin undergoes an irreversible reaction on binding Ca2 + to produce a 
photon of light (Brini, Pinton, Pozzan, & Rizzuto, 1999). Aequorin and its derivatives can be 
successfully targeted to subcellular locations (Robert, Pinton, Tosello, Rizzuto, & Pozzan, 
2000) and represented the first advance in protein-based indicators of Ca2 + appropriate for 
use in the study of Ca2 + levels in subcellular organelles. However aequorin-based indicators 
are dim relative to fluorescent GECIs and for this reason are not ideal for single-cell 
Ca2 + measurements (Ottolini, Cali, & Brini, 2014). Because the probe is consumed during the 
reaction (Bonora et al., 2013), these indicators are also poorly suited to long-term 
Ca2 + monitoring. This limits the application of aequorin-based indicators, compared with their 
fluorescent counterparts. A new class of genetically encoded calcium sensors named GAP 
(GFP-Aequorin Protein) are capable of both Ca2 +-dependent luminescence or fluorescence 
(Rodriguez-Prados, Rojo-Ruiz, Aulestia, Garcia-Sancho, & Alonso, 2015). The ability to perform 
mean cell population luminescence in conjunction with fluorescence measurements may aid 
the identification of between-experiment variability (Rodriguez-Prados et al., 2015). 
 
4.2.2 Förster Resonance Energy Transfer-Based GECIs 
Fluorescent GECIs were first developed more than 15 years ago (Miyawaki et al., 1997; 
Romoser, Hinkle, & Persechini, 1997) and exploited the phenomenon of Förster resonance 
energy transfer (FRET). This occurs when excitation of a donor fluorophore enables 
nonradiative energy transfer to allow fluorescence of a closely linked second acceptor 
fluorescent protein (Zhang, Campbell, Ting, & Tsien, 2002). FRET-based Ca2 + sensors often link 
two fluorophores with overlapping excitation/emission spectra via a Ca2 +-binding domain. 
Measurement of Ca2 + can be achieved by monitoring the change in FRET signal as a result of 
a conformational change with Ca2 + binding (Romoser et al., 1997). The first major family of 
FRET-based indicators was termed cameleons, consisting of a blue and green fluorescent 
protein linked by calmodulin fused to M13, a myosin light chain kinase-binding peptide 
(Miyawaki et al., 1997). Early versions of cameleons suffered from pH sensitivity, low signal, 
and photobleaching (Demaurex, 2005; Mank & Griesbeck, 2008), subsequent versions 
reduced some of these limitations (Palmer, Qin, Park, & McCombs, 2011). 
One advantage of FRET-based genetically encoded calcium sensors is the possibility 
of ratiometric imaging (and thus a superior ability to approximate absolute free 
Ca2 + concentrations) (Rose, Goltstein, Portugues, & Griesbeck, 2014). Ratiometric 
measurements with FRET sensors can be used to resolve motion artifacts or variations in 
sensor expression among a tissue population, which can be an advantage for in vivo 
experiments (Lutcke et al., 2010; Rose et al., 2014). However, these indicators generally have 
a lower signal-to-noise ratio, decreased brightness and slower kinetics compared to single 
fluorophore GECIs (Ai, 2015; Tian, Akerboom, Schreiter, & Looger, 2012; Tian, Hires, et al., 
2012). FRET-based GECIs have a large spectral bandwidth, limiting capacity to multiplex with 
fluorescent indicators targeting other parameters (Rose et al., 2014; Tian, Akerboom, et al., 
2012). 
 
4.2.3 Single-Wavelength Fluorescent GECIs 
Single fluorescent protein calcium indicators were first developed following the 
observation that GFP can have proteins inserted in its beta-barrel structure and still maintain 
the ability to fluoresce (Baird, Zacharias, & Tsien, 1999). This led to the development of the 
Camgaroo family of indicators, consisting of a single fluorophore (circular permutation of 
yellow fluorescent protein) modified to contain a calmodulin Ca2 +-binding domain within its 
beta-barrel structure (Baird et al., 1999). Although this series formed the basis for future GECI 
classes, Camgaroos suffered from sensitivity to pH and low brightness (Mank & Griesbeck, 
2008; Whitaker, 2010). The Pericams were a subsequent family of single-fluorophore 
indicators, although these offered some improvements over Camgaroo sensors, pH 
sensitivity, and low brightness limited use (Mank & Griesbeck, 2008; Pologruto, Yasuda, & 
Svoboda, 2004; Whitaker, 2010). 
First developed at a similar time to the Pericams, another class of single fluorescent 
protein GECIs are termed GCaMP. These Ca2 + sensors consist of a circular permutation of GFP 
linked to a M13 fragment of myosin light chain kinase at the N-terminus and calmodulin-
binding domain at the C-terminus (Nakai, Ohkura, & Imoto, 2001). Like other early GECIs, the 
first series of GCaMP suffered issues with low brightness, temperature sensitivity, poor 
expression, and pH sensitivity (Tallini et al., 2006; Whitaker, 2010). An advance came in 2009 
with the development of GCaMP3, with several improvements including increased protein 
stability and dynamic range (Tian et al., 2009). The subsequent GCaMP5 indicators were 
developed with further improvements in brightness, dynamic range, and affinity for 
Ca2 + (Akerboom et al., 2012). The most recent version of this series, GCaMP6, was developed 
through screening variants with point mutations from the GCaMP5G structure (Chen et al., 
2013). Three of these were selected, named GCaMP6f (fast), GCaMP6m (medium), and 
GCaMP6s (slow), distinguished by their response kinetics in detecting Ca2 + transients (Chen et 
al., 2013). Though GCaMP6s has slower kinetics than the other GCaMP6 variants, it is the 
most sensitive of the three sensors (Chen et al., 2013). In contrast, the fast kinetics of 
GCaMP6f is likely the preferred variant for the measurement of rapid Ca2 + oscillations, like 
those observed in neurons. 
Compared with FRET-based indicators, single fluorescent protein indicators have the 
advantage of generally more favorable dynamic range, in part due to their typically lower 
basal fluorescence. This also reduces the potential for photobleaching in long-term assays. 
However, given measurements of fluorescence intensity is influenced by sensor expression, 
single fluorescent protein indicators are arguably still best suited to relative measurements 
of intracellular free Ca2 + (Abdul, Ramlal, & Hoosein, 2008; Whitaker, 2010). 
 
5 New GECIs 
In recent years, there have been considerable gains in performance for genetically 
encoded Ca2 + indicators. A significant improvement came from the development of the 
GCaMP6 indicators, as for the first time, these indicators had comparable performance (Chen 
et al., 2013) with regards to sensitivity and kinetics compared with leading small molecular 
Ca2 +-sensitive dyes (e.g., Fluo-4). GCaMP6 indicators have widespread use (Lee, Huang, & 
Fitzpatrick, 2016; Montijn, Meijer, Lansink, & Pennartz, 2016; Sidik et al., 2016; Theis et al., 
2016) and several variants on the original series have since been developed, targeted to 
various locations. Table 1 outlines the properties of some of these indicators, along with 
several other GECIs discussed in this review. 
Recently, there has also been considerable interest in developing high-performance 
GECIs capable of fluorescence emission in longer wavelength hues (Zhao et al., 2011), 
allowing the potential for multicolor Ca2 + imaging. This has a major advantage in studies 
seeking to investigate the Ca2 + signaling interactions between two cell populations, or 
between two cellular compartments (e.g., cytosolic vs mitochondrial Ca2 + levels; Li et al., 
2014). One example includes the GECO series of indicators, which are available with red, blue, 
or green intensiometric emission (Zhao et al., 2011). Red-shifted indicators have the added 
advantage of greater tissue penetration, reduced phototoxicity, and less light scattering in 
vivo (Oheim et al., 2014; Pendin, Greotti, Filadi, & Pozzan, 2015; Rodriguez et al., 2017). Newly 
developed cytosolic red Ca2 + indicators have significantly improved performance relative to 
previous red indicators (Dana et al., 2016; Inoue et al., 2015). These include R-CaMP2 (Inoue 
et al., 2015), jRGECO1a (Dana et al., 2016), jRCaMP1a, and jRCaMP1b (Dana et al., 2016). R-
CaMP2 and jRGECO1a are derived from the mApple fluorophore, a protein capable of 
photoswitching (Shaner et al., 2008), which may limit the use of these indicators in certain 
protocols (Dana et al., 2016). jRCaMP1a and jRCaMP1b have a different fluorophore, mRuby, 
and were derived by screening mutational variants of RCaMP1h (Dana et al., 2016). These 
sensors have distinct properties which may make them suitable for different applications; 
jRCaMP1a has a higher affinity for Ca2 + (Kd 214 nM), while jRCaMP1b has a greater dynamic 
range (Dana et al., 2016). 
Other developments in GECIs include the Fast-GCaMPs (Sun et al., 2013), later 
improved to combine the properties of brightness associated with GCaMP6f (Badura et al., 
2014). A GCaMP8 (Ohkura et al., 2012) indicator is also available, though the alternative 
numbering structure employed by this group should not suggest superiority to GCaMP6 
(Broussard, Liang, & Tian, 2014). It has also recently been identified that some GCaMP 
variants can be photoconverted from green to red, by prolonged exposure with blue-green 
light at 450–500 nm (Ai et al., 2015). Importantly, these indicators remain Ca2 + sensitive (Ai et 
al., 2015). This can allow the “highlighting” of selective cells among a population in vivo, 
potentially useful for repeated measurements or distinguishing individual cell morphology 
(Berlin et al., 2015; Hoi, Matsuda, Nagai, & Campbell, 2013). Differentiating individual cells 
could also be achieved by the newly developed photoactivatable GCaMP6 series, where cells 
expressing the Ca2 + sensor can be selectively highlighted via excitation at 405 nm (Berlin et 
al., 2015). Further diversity has come from the targeting of several modern GECIs to various 
intracellular organelles as described later. In many cases, this has been possible through the 
development of indicators with lower affinities for Ca2 + ions, thus avoiding saturation in 
organelles with high free Ca2 + levels in their lumen (e.g., the ER). 
 
6 Targeting GECIs 
One of the advantages of all GECIs is their ability to be targeted to specific tissues, cell 
populations, subcellular regions, or organelles. The concept of targeting GECIs has been 
around for some time; however with recent advances, new efforts have been made to 
develop sensors that are capable of reliable Ca2 + measurement at various cellular sites. GECIs 
have been targeted to the mitochondria, ER, nucleus, Golgi apparatus, endosomes, 
peroxisomes, and the subplasmalemmal domain (Demaurex, 2005; Suzuki et al., 2016; 
Williams, Monif, & Richardson, 2013). Given there is a large variation in the resting-free 
Ca2 + levels between different subcellular organelles (e.g., cytosol ~ 100 nM vs the ER 
~ 500 μM (Carafoli, 1987; Vandecaetsbeek, Vangheluwe, Raeymaekers, Wuytack, & 
Vanoevelen, 2011)), care needs to be taken when selecting a GECI to measure Ca2 + changes, 
with an appropriate Kd required for the expected Ca2 +level (to avoid indicator 
saturation). Fig. 2 highlights some examples of targeted GECIs for various intracellular 
organelles and subcellular locations. Environmental differences such as pH can also vary 
between organelles and this must also be considered in indicator selection (Perez Koldenkova 
& Nagai, 2013). The effect of the addition of a targeting sequence likewise needs to be 
carefully considered, given the possibility of obstruction of normal sensor activity (Suzuki et 
al., 2016). Low-affinity indicators have been developed for measurement of free Ca2 + in the 
ER lumen. One example are the CEPIA series, which have three variants; red (R-CEPIA1er), 
green (G-CEPIA1er), or the ratiometric blue/green (GEM-CEPIA1er) (Suzuki et al., 2014). The 
dual emission of GEM-CEPIA1er enables the ability to normalize for factors such as variations 
in sensor expression (Suzuki et al., 2014). GAP Ca2 + indicators have also been targeted to the 
ER and Golgi apparatus (Navas-Navarro et al., 2016; Rodriguez-Garcia et al., 2014) and 
likewise several FRET-based cameleons have been targeted to various organelles successfully 
(Demaurex & Frieden, 2003). Aside from organellar targeting, it can be advantageous to 
monitor Ca2 + levels at other locations within the cell, such as the plasma membrane. Indeed 
localized Ca2 + microdomains located near the plasma membrane can have signaling 
functions independent of global [Ca2 +]CYT changes (Rizzuto & Pozzan, 2006). Several GECIs have 
been targeted to this location (Akerboom et al., 2012; Heim & Griesbeck, 2004; Nagai et al., 
2004; Shigetomi et al., 2010). A recent study also described single channel recording of 
STIM1/ORAI1 interaction in HEK-293A cells with three different GECI-ORAI1 fusions (Dynes et 
al., 2016). 
The increasing array of GECIs available continues to expand the choices available for 
Ca2 + measurement. However, indicators need to be selected based on the specific 
experimental requirements. Consideration must be given to factors such as the importance 
of absolute quantitation, impact of phototoxicity, location of Ca2 + changes to be measured, 
and the need for multicolor imaging. 
 
7 Application of GECIs in the Assessment of Calcium 
Homeostasis in Disease 
The application of GECIs has often been focused on studies investigating neuronal 
physiology. Such work often takes advantage of the ability of GECIs to be targeted to specific 
cell populations or cell locations, in addition to the suitability of GECIs for chronic imaging (a 
significant limitation of small molecule fluorescent indicators). There are numerous examples 
of GECIs being used to better understand the nature of Ca2 + signaling changes in disease using 
both in vitro and in vivo models. Some exemplar studies are outlined later which provide 
insights into how other areas of biomedical research may utilize GECIs to better understand 
the role of Ca2 + homeostasis remodeling in disease. 
In astrocyte neuronal death induced by oxygen deprivation, the plasma membrane 
targeted Lck-GCaMP6s sensor was able to identify spontaneous Ca2 +transients, accompanying 
mitochondrial disruption (O'Donnell et al., 2016). These were of two distinct phenotypes. The 
first, a fast transient propagating between mitochondria, while the latter, a newly identified 
localized Ca2 +oscillation at plasma membrane immediately adjacent to mitochondria 
(O'Donnell et al., 2016). In pluripotent stem cell-derived cardiomyocytes, GCaMP5G was 
expressed to identify proarrhythmic disruption of Ca2 + signaling induced by pharmacological 
agents (Shinnawi et al., 2015). By coexpressing with a genetically encoded voltage indicator, 
this model provides the ability to screen compounds that disrupt normal Ca2 + dynamics or 
membrane depolarization (Shinnawi et al., 2015). 
GECIs have also been used to characterize Ca2 + changes associated with viral infection 
(Perry, Ramachandran, Utama, & Hyser, 2015). By expressing both R-CEPIA1er (targeting the 
ER) and the cytosolic GCaMP5G (or GCaMP6s) sensor, Perry et al. observed attenuated 
adenosine triphosphate (ATP)-induced Ca2 + transients at the cytosol and ER of both MA-104 
and HeLa cells following infection with rotavirus or poliovirus (Perry et al., 2015). The authors 
also demonstrated the GECIs could be used to monitor Ca2 + changes during live cell imaging 
of viral infection measured over 16 h, identifying increased Ca2 +oscillations with rotavirus 
infection, which could be attenuated with inhibitors of Ca2 + influx (Perry et al., 2015). 
Application of GECIs has extended to other research areas. The expression of GCaMP 
indicators in somatosensory neurons of live mice enabled the observation of differential 
neuronal responses dependent on the type of painful stimuli, suggesting future use of this 
GECI-based model could help elicit the neuronal mechanisms of distinct pain pathways 
(Emery et al., 2016). Another example used expression of GCaMP indicators in Toxoplasma 
gondii to screen compounds capable of disrupting Ca2 + signaling, enabling the authors to 
identify novel antiparasitic compounds (Sidik et al., 2016). 
As already discussed, there is an increasing awareness of the importance of the nature 
of calcium signaling changes rather than changes in expression of calcium channels in cancer 
(Stewart et al., 2015); however, GECIs remain relatively underutilized in this research area. Of 
the few studies that have used GECIs in cancer cells, most have been in breast cancer cells. 
Indeed over 10 years ago, D1ER (an ER-targeted GECI) was used to monitor ER Ca2 + changes 
because of Bcl-2-mediated ER stress in MCF7 cells (Palmer et al., 2004). The authors identified 
that Bcl-2 reduced Ca2 + levels in the ER by increasing Ca2 + leak from internal stores (Palmer et 
al., 2004) likely via IP3Rs. A more recent example is the use of a mitochondrial targeted 
GCaMP6f indicator to identify that mitochondrial calcium uniporter silencing attenuates 
mitochondrial calcium uptake in MDA-MB-231, MDA-MB-468, and BT-549 breast cancer cells 
(Tosatto et al., 2016). 
Arguably one of the greatest advantages for GECIs is their ability to be used in chronic 
measurements of Ca2 +, a property that favors the use of these sensors in vivo. Repeated 
Ca2 + measurement can be achieved through intravital microscopy (Pittet & Weissleder, 2011). 
This typically involves the implantation of a window in the model organism allowing the 
visualization of Ca2 + changes (Karreman, Hyenne, Schwab, & Goetz, 2016). For example, 
implantation of a cranial window was used in an Alzheimer's disease mouse model (APP/PS1 
mice) to image neurons expressing the GCaMP6m sensor (Liebscher, Keller, Goltstein, 
Bonhoeffer, & Hubener, 2016). This enabled the identification of various neuronal 
Ca2 + alterations in this model, including a reduction in the magnitude of neuronal responses 
in response to visual and motor cues (Liebscher et al., 2016). Expression of the cameleon 
indicator YC3.6 in neurons of APP mice (another Alzheimer's disease model) also made use of 
intravital imaging, finding increased Ca2 + levels in the dendrites and axons adjacent to 
amyloid-β plaques with associated morphological changes in part the result of these increases 
(Kuchibhotla et al., 2008). YC3.6 has also been used in a mouse model of familial hemiplegic 
migraine type 1 (Eikermann-Haerter et al., 2015). In vivo imaging was achieved via a cranial 
window allowing the identification of Ca2 + overload associated with changes in Cav2.1 
channels (Eikermann-Haerter et al., 2015). Given the role of calcium signaling in the heart, 
there is also potential for use of GECIs in vivo in this context (see recent review, Kaestner et 
al., 2014) and protocols have been published outlining intravital imaging of the heart in live 
mice (e.g., Vinegoni, Aguirre, Lee, & Weissleder, 2015). One example used the expression of 
GCaMP3 in human embryonic stem cell-derived cardiomyocytes to confirm functional activity 
of these cells following transplantation to regenerate myocardium tissue damage in guinea-
pigs (Shiba et al., 2012). 
Intravital imaging is also technique to be exploited in in vivo cancer models, where 
the ability to chronically image cancer cells could further our understanding of tumor 
progression and metastasis (Ellenbroek & van Rheenen, 2014). An example of this potential 
is seen by the use of an intravital chamber in p53 knockout mice to measure the disruption of 
Ca2 + dynamics during apoptosis, using the small molecule dye fura-2 (Giorgi et al., 2015). 
Given the recent progress in both GECIs and intravital imaging, there is likely to be an increase 
in the use of these sensors to investigate Ca2 + signaling changes in cancer in vivo. 
 
8 GECIs and Biomolecular Screening 
Only a few published studies have used GECIs in the context of high-throughput 
screening in drug discovery; however, there has been wide use of small molecule 
Ca2 + indicators in a variety of G-protein-coupled receptors and ion channel-based 
biomolecular screens (Behrendt, Germann, Gillen, Hatt, & Jostock, 2004; Herington et al., 
2015; Wang et al., 2015). This is a strong indicator of the utility of GECIs in biomolecular 
screening, given the recent advances in GECIs as discussed throughout this review. 
One example, where GECIs have been used in a cell-based screen, was described 
by Honarnejad et al. (2013). This involved the stable expression of the FRET-based cameleon 
YC3.6 in HEK-293 cells expressing a PS1 gene mutation associated with Alzheimer's disease. 
PS1 mutation can augment ER calcium homeostasis, evidenced by a reduction of the 
magnitude Carbachol-induced ER calcium release (Honarnejad et al., 2013). This group 
screened 20,000 compounds and was able to identify 53 hits capable of causing recovery of 
the wild-type ER calcium release, by examining those with the highest FRET signal 
(Honarnejad et al., 2013). RCaMP1h, a red fluorescent GECI, has recently been used to screen 
genes capable of altering synaptic vesicles using the model organism Caenorhabditis 
elegans using high content imaging (Wabnig, Liewald, Yu, & Gottschalk, 2015). By 
incorporating RCaMP1h into postsynaptic body wall muscle, RNA interference allowed 
identification of genes able to alter synaptic transmission following stimulation of cholinergic 
neurons. This assay was not without challenges; nematodes were imaged in microwells made 
from agar and despite identifying five target genes capable of altering Ca2 +, this did not 
translate to a strong phenotype of altered synaptic vesicle trafficking (Wabnig et al., 2015). It 
is likely that some GECIs are already part of biodiscovery projects within pharmaceutical 
companies and have not yet been described in journal articles, as has been done with small 
molecule-based probes (Herington et al., 2015). However, it is clear that further application 
of GECIs in academia and industry will help accelerate the discovery of a new generation of 
pharmacological agents capable of modulating calcium signaling in disease. 
 
9 Conclusion 
The advances in GECIs have been exponential over recent years. Each year 
incremental improvements are made and new GECIs released. Further development in the 
properties of fluorescent proteins (including far-red and infrared protein indicators) will 
enhance this diversity of available Ca2 + sensors (Rodriguez et al., 2017). This will assist 
researchers to avoid spectral overlap, an increasingly important consideration for 
simultaneous cytosolic/organellar Ca2 + measurements (Rose et al., 2014). Advancement will 
also come from improvements in instrument capabilities and enhancement of software 
platforms for streamlining analysis. 
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 Fig. 1 Schematic representation of a mammalian cell, highlighting some of the main 
Ca2 + channel families. Ca2 + channels in conjunction with Ca2 + pumps, exchangers, and other 
regulators are responsible for intracellular calcium signaling. Through the action of these 
proteins, Ca2 + concentration gradients are apparent across the plasma membrane and at 
intracellular organelles such as the endoplasmic reticulum, which can be altered by these 
channels. 
Adapted from Stewart, T. A., Yapa, K. T., & Monteith, G. R. (2015). Altered calcium signaling 
in cancer cells. Biochimica et Biophysica Acta, 1848(10), 2502–2511. 
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Indicator Class Fluorophore(s) Max 
Dynamic 
Range 
Kd (nM) Excitation 
(nm) 
Emission 
(nm) 
References 
4mtD3cpv 
 
FRET ECFP/cpVenus 5.1 760 433 475,528 Palmer et al. 
(2006) 
CEPIA1er G-CEPIA1er Intensiometric cpEGFP 4.7 672,000 497 511 Suzuki et al. (2014) 
GEM-CEPIA1er Ratiometric cpEGFP 21.7 558,000 391 462,510 Suzuki et al. (2014) 
R-CEPIA1er Intensiometric cpmApple 8.8 565,000 562 584 Suzuki et al. (2014) 
D1ER 
 
FRET ECFP,citrine — 810, 
60,000 
433 475,529 Palmer, Jin, Reed, 
and Tsien (2004) 
D4ER 
 
FRET ECFP,citrine — 195,000 435 475,540 Ravier et al. (2011) 
Fast-
GCaMPs 
Fast-GCaMP3-
RS09 
Intensiometric cpEGFP 9.5 690 497 512 Sun et al. (2013) 
Fast-GCaMP6f-
RS06 
Intensiometric cpEGFP 18.7 320 488 512 Badura, Sun, 
Giovannucci, 
Lynch, and Wang 
(2014) 
Fast-GCaMP6f-
RS09 
Intensiometric cpEGFP 25 520 488 512 Badura et al. 
(2014) 
Indicator Class Fluorophore(s) Max 
Dynamic 
Range 
Kd (nM) Excitation 
(nm) 
Emission 
(nm) 
References 
GAP goGAP1 Ratiometric/bioluminescent GFP 
variant/aequorin 
— 12,000 403,470 510 Rodriguez-Garcia 
et al. (2014) 
erGAP3 Ratiometric/bioluminescent GFP 
variant/aequorin 
3 489,000 405,470 535 Navas-Navarro et 
al. (2016) 
GCaMP3 
 
Intensiometric cpEGFP 12 840 485 510 Tian et al. (2009) 
GCaMP5G 
 
Intensiometric cpEGFP 32.7 460 485 510 Akerboom et al. 
(2012) 
 
Lck-GCaMP5G Intensiometric cpEGFP — — 485 510 Akerboom et al. 
(2012) 
GCaMP6 GCaMP6f Intensiometric cpEGFP 51.8 375 497 515 Chen et al. (2013) 
GCaMP6m Intensiometric cpEGFP 38.1 167 497 515 Chen et al. (2013) 
GCaMP6s Intensiometric cpEGFP 63.2 144 497 515 Chen et al. (2013) 
2mtGCaMP6m Intensiometric cpEGFP — 167 474 515 Hill et al. (2014) 
4mtGCaMP6f Intensiometric cpEGFP — — 497 515 Tosatto et al. 
(2016) 
Lck-GCaMP6s Intensiometric cpEGFP — 144 497 515 O'Donnell, Jackson, 
and Robinson 
(2016) 
sPA-GCaMP6f Intensiometric cpEGFP — 681 480 513 Berlin et al. (2015) 
Indicator Class Fluorophore(s) Max 
Dynamic 
Range 
Kd (nM) Excitation 
(nm) 
Emission 
(nm) 
References 
GCaMP8 
 
Intensiometric cpEGFP 37.5 200 488 — Ohkura et al. 
(2012) 
GECO G-GECO1 Intensiometric cpEGFP 25 749 496 512 Zhao et al. (2011) 
GEM-GECO1 Ratiometric cpEGFP 110 340 390 455,511 Zhao et al. (2011) 
R-GECO1 Intensiometric cpmApple 16 482 561 589 Zhao et al. (2011) 
ER-LAR-GECO1 Intensiometric cpmApple 10 24,000 561 589 Wu et al. (2014) 
mito-LAR-
GECO1.2 
Intensiometric cpmApple 8.7 12,000 557 584 Wu et al. (2014) 
NLS-R-GECO1 Intensiometric cpmApple 16 482 561 589 Zhao et al. (2011) 
Orai-G-GECO1 Intensiometric cpEGFP 25 749 496 512 Dynes, 
Amcheslavsky, and 
Cahalan (2016) 
Orai-G-
GECO1.2 
Intensiometric cpEGFP 23 1150 498 513 Dynes et al. (2016) 
go-D1cpv 
 
FRET ECFP,cpVenus — — 425 480,520 Lissandron, Podini, 
Pizzo, and Pozzan 
(2010) 
NLS-GCaMP2 Intensiometric cpEGFP — — 480 508 Bengtson, Freitag, 
Weislogel, and 
Bading (2010) 
Indicator Class Fluorophore(s) Max 
Dynamic 
Range 
Kd (nM) Excitation 
(nm) 
Emission 
(nm) 
References 
jRCaMP1a 
 
Intensiometric cpmRuby 3.2 214 570 600 Dana et al. (2016) 
jRCaMP1b 
 
Intensiometric cpmRuby 7.2 712 570 600 Dana et al. (2016) 
jRGECO1a 
 
Intensiometric cpmApple 11.6 148 570 600 Dana et al. (2016) 
RCaMP1h 
 
Intensiometric cpmRuby 10.5 1300 571 594 Akerboom et al. 
(2013) 
R-CaMP2 
 
Intensiometric cpmApple 4.8 69 565 583 Inoue et al. (2015) 
TN-XXL 
 
FRET ECFP,cp174Citrine — 800 430 480,535 Mank et al. (2008) 
Twitch3 
 
FRET ECFP,cp174Citrine 7 250 432 475,527 Thestrup et al. 
(2014) 
Twitch4 
 
FRET ECFP,cp174Citrine 6 2800 432 475,527 Thestrup et al. 
(2014) 
YC3.6 
 
FRET ECFP,cp173Venus 5.6 250 430 480,530 Nagai, Yamada, 
Tominaga, 
Ichikawa, and 
Miyawaki (2004) 
YC-Nano50 FRET ECFP,cp173Venus 12.5 52.5 430 480,530 Horikawa et al. 
(2010) 
  
Fig. 2 Examples of genetically encoded calcium indicators targeted to intracellular 
organelles, subcellular locations, or with cytosolic localization. While not a complete list, this 
figure highlights some of the commonly applied genetically encoded calcium indicators for 
Ca2 + measurements at various cell locations. 
 
